Fusion of azurophil granules with phagosomes and activation of the tyrosine kinase Hck are specifically inhibited during phagocytosis of mycobacteria by human neutrophils.
Pathogenic mycobacteria parasitize macrophages and reside within phagosomes, which do not fuse with lysosomal granules. Mycobacteria are also internalized by neutrophils, which possess at least two types of granules, specific and azurophil granules, the latter being specialized lysosomes. Here, we investigated the ability of mycobacteria to inhibit the fusion of these granules with their phagosomes in human neutrophils. It was found that when pathogenic (Mycobacterium kansasii and Mycobacterium avium) or nonpathogenic (Mycobacterium smegmatis and Mycobacterium phlei) mycobacteria were internalized by neutrophils, they induced the inhibition of azurophil granule fusion with phagosomes even when they were serum opsonized. In contrast, secretion of specific granule content and production of O2-, both of which contribute to the neutrophil bactericidal response, were triggered. Hck is a Src family tyrosine kinase associated with azurophil granules. During internalization of zymosan, azurophil granules fused with phagosomes and Hck was activated and translocated to the phagosomal membrane, whereas in neutrophils engulfing mycobacteria, Hck did not translocate and remained unactivated. The activation of the tyrosine kinase Fgr was not affected. These results indicate that 1) pathogenic and nonpathogenic mycobacteria trigger similar bactericidal responses in neutrophils, 2) phagocytosis and fusion of azurophil granules can be uncoupled by mycobacteria, and 3) Hck could be one of the key elements of the azurophil secretory pathway that are altered during phagocytosis of mycobacteria.
N'Diaye
E N
EN
Institut de Pharmacologie et de Biologie Structurale-Centre National de la Recherche Scientifique, Unité Propre de Recherche 9062, Toulouse, France.
Darzacq
X
X
Astarie-Dequeker
C
C
Daffé
M
M
Calafat
J
J
Maridonneau-Parini
I
I
D001692:Biological Transport; D003594:Cytoplasmic Granules / Q000502:physiology*; D004789:Enzyme Activation; D005089:Exocytosis; D006801:Humans; D008561:Membrane Fusion; D008565:Membrane Proteins / Q000378:metabolism; D016253:Microscopy, Immunoelectron; D009161:Mycobacterium / Q000276:immunology* / Q000472:pathogenicity; D009162:Mycobacterium avium / Q000276:immunology / Q000472:pathogenicity; D019909:Mycobacterium kansasii / Q000276:immunology / Q000472:pathogenicity; D009168:Mycobacterium phlei / Q000276:immunology / Q000472:pathogenicity; D020102:Mycobacterium smegmatis / Q000276:immunology / Q000472:pathogenicity; D009504:Neutrophils / Q000378:metabolism / Q000382:microbiology / Q000502:physiology* / Q000648:ultrastructure; D010587:Phagocytosis / Q000502:physiology; D010588:Phagosomes / Q000382:microbiology / Q000502:physiology*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051572:Proto-Oncogene Proteins c-hck; D014774:Virulence; D015054:Zymosan / Q000494:pharmacology
D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; D015054:Zymosan; D011505:Protein-Tyrosine Kinases; C496631:HCK protein, human; D051572:Proto-Oncogene Proteins c-hck